Literature DB >> 2342057

Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.

T Miyamoto1, J Matsumoto, K Chiba, H Egawa, K Shibamori, A Minamida, Y Nishimura, H Okada, M Kataoka, M Fujita.   

Abstract

A series of 5,7-disubstituted 1-cyclopropyl-6,8-difluoro-4(1H)-oxoquinoline-3-carboxylic acids (10-36) were prepared; the C-5 substituent in these compounds comprised halo, hydroxy, mercapto, and amino groups and the C-7 functional group included variously substituted piperazines. In vitro antibacterial screening results indicated that the amino group was optimal among the C-5 substituents. A combination of the C-5 amino group and the C-7 3,5-dimethylpiperazinyl appendage in this series conferred the best overall antibacterial property with lack of adverse drug interactions. Compound 36k [named sparfloxacin, originally AT-4140, 5-amino-1-cyclopropyl-6,8-difluoro-7-(cis-3,5-dimethyl-1-piperazinyl)- 4(1H)-oxoquinoline-3-carboxylic acid] was superior to ciprofloxacin in both in vitro and in vivo potency and hence was selected as a promising candidate for an improved therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2342057     DOI: 10.1021/jm00168a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Synthesis and Antimicrobial Activity of N,N'-Bis(2-hydroxylbenzyl)-1,2-ethanediamine Derivatives.

Authors:  Musiliyu A Musa; M Omar F Khan; Arden Aspedon; John S Cooperwood
Journal:  Lett Drug Des Discov       Date:  2010-03       Impact factor: 1.150

2.  Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones.

Authors:  H Yoshida; M Bogaki; S Nakamura; K Ubukata; M Konno
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

3.  Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Authors:  J M Entenza; Y A Que; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

4.  Structure-related inhibitory effect of antimicrobial enoxacin and derivatives on theophylline metabolism by rat liver microsomes.

Authors:  Y Mizuki; I Fujiwara; T Yamaguchi; Y Sekine
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

5.  Clinical evaluation of the tolerability and efficacy of trovafloxacin compared with sparfloxacin in the treatment of lower respiratory tract infections.

Authors:  J C Shobha; T R Kumar; N Deivanayagam; R B Singh; P Waghray; P A Babu; J Bhaduri; C C Sekhar
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

6.  Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; L M Yamanaka; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

7.  Mechanism of action of quinolones against Escherichia coli DNA gyrase.

Authors:  H Yoshida; M Nakamura; M Bogaki; H Ito; T Kojima; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of sparfloxacin.

Authors:  J Shimada; T Nogita; Y Ishibashi
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

9.  Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.

Authors:  H Ito; H Yoshida; M Bogaki-Shonai; T Niga; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 10.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.